26Jan 2023
Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in HFpEF

Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in HFpEF

The REDUCE‐LAP II trial demonstrated adverse outcomes after interatrial shunt device (IASD) placement in heart failure with preserved ejection fraction (HFpEF) attributed to latent pulmonary vascular disease (PVD). Therefore, it was hypothesized that exercise‐stress cardiovascular magnetic resonance (CMR) imaging could provide a non‐invasive characterization of cardiac and pulmonary physiology for improved patient selection. Latent PVD is a feature of HFpEF and is associated with impaired RV functional reserve, global diastolic filling and LV‐CI. This can be quantified by CMR and used to identify patients likely to benefit from IASD implantation.

  • #cardiology

Like

Save

Share